Market Overview

Benzinga's Top Initiations

Related TINY
UPDATE: Ascendiant Capital Markets Reiterates Buy Rating, Lowers PT on Harris & Harris Group
UPDATE: Ascendiant Capital Markets Initiates Harris & Harris Group at Buy with $4.50 on Catalysts
Related GEVA
Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
Synageva BioPharma's (GEVA) CEO Sanj Patel on Q4 2014 Results - Earnings Call Transcript (Seeking Alpha)

Aegis Capital initiated coverage on shares of Harris & Harris Group (NASDAQ: TINY) with a “buy” rating. Harris & Harris Group's shares closed at $3.71 yesterday. Harris & Harris Group's trailing-twelve-month revenue is $510.56 thousand.

Piper Jaffray initiated coverage on shares of Synageva Biopharma (NASDAQ: GEVA) with an “overweight” rating. Synageva Biopharma's stock closed at $48.76 yesterday. Synageva Biopharma had $138.86 million in total cash for the latest quarter.

Wunderlich Securities initiated coverage on shares of American Capital Mortgage Investment (NASDAQ: MTGE) with a “buy” rating. American Capital Mortgage Investment's shares closed at $24.84 yesterday. American Capital Mortgage Investment's trailing-twelve-month operating margin is 87.78%.

Credit Suisse initiated coverage on shares of Orexigen Therapeutics (NASDAQ: OREX) with an “outperform” rating. Orexigen's shares closed at $4.91 yesterday. Orexigen's trailing-twelve-month revenue is $3.43 million.

Latest Ratings for TINY

Mar 2013Ascendiant CapitalMaintainsBuy
Nov 2012Ascendiant Capital MarketsMaintainsBuy
Sep 2012Aegis CapitalInitiates Coverage onBuy

View More Analyst Ratings for TINY
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings


Related Articles (MTGE + GEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content